Also see: ADP, Amdocs, Cree: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Apple ( AAPL) estimates were increased through 2012 at Needham. Company should see better iPad and Mac shipments, Needham said. Maintain $450 price target.

Cytec ( CYT) estimates, target were cut through 2012 at Jefferies. Company could face further weakness in its coatings business, Jefferies said. Buy rating and new $64 price target.

DuPont ( DD) estimates were increased at Jefferies through 2012. Company is realizing higher TiO2 prices, Jefferies said. Buy rating and $64 price target.

Forest Laboratories ( FRX) estimates, target were increased at Credit Suisse. Shares now seen reaching $46, and estimates were also increased on M&A interest by larger peers. Credit Suisse said.

Garmin ( GRMN) estimates, target were lowered at Goldman Sachs. Shares now seen reaching $30. Estimates also cut, following the warning from TomTom, Goldman said. Neutral rating.

Grainger ( GWW) estimates, target were raised at UBS. Shares now seen reaching $156. Estimates also increased on good opportunities on margins, UBS said. Neutral rating.

Huntsman ( HUN) estimates, target were raised at Jefferies. Shares now seen reaching $26. Estimates also increased, given higher TiO2 prices, Jefferies said. Buy rating.

Johnson Controls ( JCI) estimates, target were increased at Piper Jaffray. Shares now seen reaching $51. Estimates were also increased on stronger-than-expected start-stop battery demand, Piper Jaffray said. Overweight rating.

Jacobs Engineering ( JEC) estimates, target cut at UBS. Shares now seen reaching $45. Estimates also lowered, as macro pressures remain UBS said. Neutral rating.

Marathon Oil ( MRO) estimates were boosted through 2013 at UBS. Improved refining margin outlook, UBS said. Maintain Buy rating and $60 price target.

Teva Pharmaceutical ( TEVA) estimates were lowered through 2012 at Jefferies. Stock is down 16% over the past year, even though the company has made positive strategic moves, Jefferies said. Hold rating and $53 price target.

End of report.
This article was written by a staff member of TheStreet.